See more : Agios Pharmaceuticals, Inc. (0HB0.L) Income Statement Analysis – Financial Results
Complete financial analysis of DiaMedica Therapeutics Inc. (DMAC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DiaMedica Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sichuan Goldstone Asia Pharmaceutical Inc. (300434.SZ) Income Statement Analysis – Financial Results
- Technogym S.p.A. (TCCHF) Income Statement Analysis – Financial Results
- ATI Physical Therapy, Inc. (ATIP-WT) Income Statement Analysis – Financial Results
- Global Lights Acquisition Corp Unit (GLACU) Income Statement Analysis – Financial Results
- ADMA Biologics, Inc. (ADMA) Income Statement Analysis – Financial Results
DiaMedica Therapeutics Inc. (DMAC)
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 500.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 160.62K | 25.74K | 25.68K | 33.88K |
| Cost of Revenue | 30.00K | 25.00K | 24.00K | 21.00K | 21.00K | 0.00 | 4.00K | 2.21K | 4.46K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -30.00K | -25.00K | -24.00K | -21.00K | -21.00K | 500.00K | -4.00K | -2.21K | -4.46K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 160.62K | 25.74K | 25.68K | 33.88K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 13.11M | 7.84M | 8.77M | 8.31M | 7.90M | 4.52M | 3.21M | 1.76M | 886.07K | 3.71M | 3.78M | 5.21M | 2.33M | 803.98K | 1.37M | 1.04M | 1.07M | 617.26K | 22.75K | 462.00K |
| General & Administrative | 8.16M | 6.16M | 4.88M | 4.39M | 3.69M | 2.74M | 1.31M | 718.05K | 423.35K | 1.12M | 2.54M | 2.53M | 2.08M | 1.30M | 1.00M | 618.54K | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.16M | 6.16M | 4.88M | 4.39M | 3.69M | 2.74M | 1.31M | 718.05K | 423.35K | 1.12M | 2.54M | 2.53M | 2.08M | 1.30M | 1.00M | 618.54K | 1.38M | 192.37K | 177.78K | 168.91K |
| Other Expenses | 0.00 | 353.00K | 82.00K | -205.00K | -856.00K | -68.00K | 6.00K | 221.90K | 3.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.58K | -4.89K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 21.27M | 14.00M | 13.65M | 12.49M | 10.74M | 6.05M | 4.28M | 2.48M | 1.31M | 4.83M | 7.43M | 10.11M | 6.71M | 3.84M | 2.40M | 1.69M | 2.47M | 812.95K | 228.69K | 637.31K |
| Cost & Expenses | 21.27M | 14.00M | 13.65M | 12.49M | 10.74M | 6.05M | 4.28M | 2.48M | 1.31M | 4.83M | 7.43M | 10.11M | 6.71M | 3.84M | 2.40M | 1.69M | 2.47M | 812.95K | 228.69K | 637.31K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.73K | 1.74K | 10.54K | 14.73K | 41.03K | 51.44K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.25 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 48.38K | 43.96K | 0.00 | 7.73K | 2.72K | 12.57K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.60K | 36.59K |
| Depreciation & Amortization | 30.00K | 25.00K | 24.00K | 21.00K | 21.00K | 15.00K | 4.00K | 2.21K | 4.11K | 2.47K | 1.11M | 2.37M | 2.30M | 1.67M | 30.20K | 26.74K | 18.35K | 3.32K | 28.15K | 6.41K |
| EBITDA | -19.31M | -13.98M | -13.62M | -12.24M | -10.60M | -5.64M | -4.26M | -2.15M | -1.50M | -5.01M | -6.51M | -7.70M | -4.51M | -3.32M | -2.27M | -2.34M | -2.29M | -783.89K | -190.26K | -630.30K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,098.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,426.62% | -3,045.78% | -680.92% | -1,762.12% |
| Operating Income | -21.27M | -14.00M | -13.65M | -12.70M | -11.59M | -6.76M | -4.52M | -2.48M | -1.31M | -4.83M | -7.43M | -10.11M | -6.71M | -3.84M | -2.40M | -1.69M | -2.31M | -787.21K | -203.01K | -603.43K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,352.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,438.05% | -3,058.67% | -790.56% | -1,781.04% |
| Total Other Income/Expenses | 1.93M | 353.00K | 82.00K | 434.00K | 975.00K | 747.00K | 259.00K | 280.63K | -104.38K | -185.41K | -230.99K | 37.57K | -174.26K | -422.84K | 101.28K | -168.32K | 57.19K | -12.38K | 10.28K | 66.55K |
| Income Before Tax | -19.34M | -13.65M | -13.56M | -12.27M | -10.62M | -5.65M | -4.26M | -2.20M | -1.43M | -4.78M | -7.41M | -10.05M | -6.61M | -4.27M | -2.44M | -1.85M | -2.31M | 0.00 | -192.73K | -570.16K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,130.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,440.21% | 0.00% | -750.53% | -1,682.83% |
| Income Tax Expense | 43.00K | 28.00K | 28.00K | 27.00K | 31.00K | 80.00K | -9.00K | 22.31K | 12.45K | 42.28K | 7.73K | 2.72K | 12.57K | 499.08K | 41.69K | 163.43K | 20.20K | -9.19K | 17.87K | 69.86K |
| Net Income | -19.38M | -13.68M | -13.59M | -12.29M | -10.65M | -5.73M | -4.26M | -2.22M | -1.44M | -4.82M | -7.41M | -10.05M | -6.61M | -4.27M | -2.44M | -1.85M | -2.33M | -778.02K | -210.60K | -640.02K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,146.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,452.78% | -3,022.96% | -820.13% | -1,889.02% |
| EPS | -0.60 | -0.52 | -0.65 | -0.78 | -0.89 | -0.74 | -0.72 | -0.47 | -0.40 | -1.55 | -2.71 | -4.11 | -2.93 | -2.98 | -2.54 | -2.04 | -2.91 | -0.89 | -0.50 | -2.35 |
| EPS Diluted | -0.60 | -0.52 | -0.65 | -0.78 | -0.89 | -0.74 | -0.72 | -0.47 | -0.40 | -1.55 | -2.71 | -4.11 | -2.93 | -2.98 | -2.54 | -2.04 | -2.91 | -0.89 | -0.50 | -2.35 |
| Weighted Avg Shares Out | 32.57M | 26.44M | 20.77M | 15.68M | 11.99M | 7.74M | 5.94M | 4.74M | 3.62M | 3.11M | 2.73M | 2.45M | 2.26M | 1.43M | 960.48K | 909.72K | 802.30K | 876.03K | 420.15K | 272.16K |
| Weighted Avg Shares Out (Dil) | 32.57M | 26.44M | 20.77M | 15.68M | 11.99M | 7.74M | 5.94M | 4.74M | 3.62M | 3.11M | 2.73M | 2.45M | 2.26M | 1.43M | 960.48K | 909.72K | 802.30K | 876.03K | 420.15K | 272.16K |
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the year ended December 31, 2023. Management will host a...
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke (AIS), today announced a poster presentation of the design and rationale for ReMEDy2, the planned pivotal...
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with...
DiaMedica Therapeutics Inc. (DMAC) Q3 2023 Earnings Call Transcript
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q3 2023 Earnings Call Transcript November 14, 2023 8:00 AM ET Company Participants Rick Pauls - President and CEO Scott Kellen - CFO Conference Call Participants Thomas Flaten - Lake Street Capital Alexander Nowak -...
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the quarter ended September 30, 2023. Management will host a...
DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, today announced that Rick Pauls, its President and CEO and Dave Wambeke, its Chief Business Officer...
DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its third quarter 2023 financial results will be released after the markets close...
DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Ambarish Shah, Ph.D. as Chief Technology Officer. Dr. Shah will lead the development of...
DiaMedica Therapeutics to Participate at Lake Street's 7th Annual Best Ideas Growth Conference
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders, today announced that Rick Pauls, its President and CEO will be participating at Lake Street Capital Market's 7th Annual Best Ideas Growth...
Is DiaMedica Therapeutics (DMAC) Stock Outpacing Its Medical Peers This Year?
Here is how DiaMedica Therapeutics, Inc. (DMAC) and DermTech, Inc. (DMTK) have performed compared to their sector so far this year.
Source: https://incomestatements.info
Category: Stock Reports